Washington · SB 5594 · 2025Did Not Pass

Biosimilar Medicines Rules

Would have set rules for how biosimilar medicines can be substituted for brand-name biologics; did not become law.

Topics

Find your representatives and let them know how this issue affects you.

Strengthens state oversight of the 340B program so discounted drug pricing intended for safety-net clinics and hospitals actually reaches patients.

Sets safety standards for pharmacies that compound custom medications to reduce contamination and dosing errors.

Allows pharmacists to dispense a short emergency supply of insulin to patients who run out and can't immediately reach their doctor.